Market Research Logo

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016’, provides in depth analysis on Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted pipeline therapeutics.

The report provides comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
    • The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Human Cytomegalovirus Envelope Glycoprotein B (gB) Overview
Therapeutics Development
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Stage of Development
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Therapy Area
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Indication
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Companies
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccines Inc
Vical Incorporated
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
ASP-0113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyMVectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1501A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPM-2001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Projects
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Featured News & Press Releases
Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review
Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington
Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference
Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology
Nov 06, 2015: VBI Vaccines to Present Update and New Data Supporting its CMV Vaccine Program at the World Vaccine Congress Europe
Aug 26, 2015: VBI Vaccines to Provide an Update on its CMV Vaccine Program at the Tenth Annual IMVACS Summit
May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients
Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference
Apr 09, 2015: VBI Vaccines Announces New Data Supporting the Manufacture of Its Prophylactic CMV Vaccine Candidate
Nov 24, 2014: VBI To Present At The LD Micro Conference
Sep 15, 2014: New Data Supporting VBI's Prophylactic Cytomegalovirus (CMV) Vaccine Candidate (VBI-1501A) Presented at the 54th ICAAC Conference in Washington, D.C.
Mar 27, 2014: VBI Begins GMP Tech Transfer to Paragon Bioservices
Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by Trellis Bioscience, Inc., H2 2016
Pipeline by Vakzine Projekt Management GmbH, H2 2016
Pipeline by VBI Vaccines Inc, H2 2016
Pipeline by Vical Incorporated, H2 2016
Dormant Projects, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report